Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 1
2013 2
2016 2
2017 2
2018 2
2021 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

9 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean schelter e (153 results)?
2021 update to HIV-TRePS: a highly flexible and accurate system for the prediction of treatment response from incomplete baseline information in different healthcare settings.
Revell AD, Wang D, Perez-Elias MJ, Wood R, Cogill D, Tempelman H, Hamers RL, Reiss P, van Sighem A, Rehm CA, Agan B, Alvarez-Uria G, Montaner JSG, Lane HC, Larder BA; RDI study group. Revell AD, et al. J Antimicrob Chemother. 2021 Jun 18;76(7):1898-1906. doi: 10.1093/jac/dkab078. J Antimicrob Chemother. 2021. PMID: 33792714 Free PMC article.
Week 96 results of the randomized, multicentre Maraviroc Switch (MARCH) study.
Pett SL, Amin J, Horban A, Andrade-Villanueva J, Losso M, Porteiro N, Madero JS, Belloso W, Tu E, Silk D, Kelleher A, Harrigan R, Clark A, Sugiura W, Wolff M, Gill J, Gatell J, Clarke A, Ruxrungtham K, Prazuck T, Kaiser R, Woolley I, Alberto Arnaiz J, Cooper D, Rockstroh JK, Mallon P, Emery S; MARCH study group. Pett SL, et al. HIV Med. 2018 Jan;19(1):65-71. doi: 10.1111/hiv.12532. Epub 2017 Jul 13. HIV Med. 2018. PMID: 28703491 Free article. Clinical Trial.
Results of external quality assessment for proviral DNA testing of HIV tropism in the Maraviroc Switch collaborative study.
Tu E, Swenson LC, Land S, Pett S, Emery S, Marks K, Kelleher AD, Kaye S, Kaiser R, Schuelter E, Harrigan R; MARCH Laboratory Group and the MARCH Study Group. Tu E, et al. Among authors: schuelter e. J Clin Microbiol. 2013 Jul;51(7):2063-71. doi: 10.1128/JCM.00510-13. Epub 2013 Apr 17. J Clin Microbiol. 2013. PMID: 23596247 Free PMC article.
2018 update to the HIV-TRePS system: the development of new computational models to predict HIV treatment outcomes, with or without a genotype, with enhanced usability for low-income settings.
Revell AD, Wang D, Perez-Elias MJ, Wood R, Cogill D, Tempelman H, Hamers RL, Reiss P, van Sighem AI, Rehm CA, Pozniak A, Montaner JSG, Lane HC, Larder BA; RDI Data and Study Group. Revell AD, et al. J Antimicrob Chemother. 2018 Aug 1;73(8):2186-2196. doi: 10.1093/jac/dky179. J Antimicrob Chemother. 2018. PMID: 29889249 Free PMC article.
An update to the HIV-TRePS system: the development and evaluation of new global and local computational models to predict HIV treatment outcomes, with or without a genotype.
Revell AD, Wang D, Wood R, Morrow C, Tempelman H, Hamers RL, Reiss P, van Sighem AI, Nelson M, Montaner JS, Lane HC, Larder BA; RDI Data and Study Group. Revell AD, et al. J Antimicrob Chemother. 2016 Oct;71(10):2928-37. doi: 10.1093/jac/dkw217. Epub 2016 Jun 20. J Antimicrob Chemother. 2016. PMID: 27330070 Free PMC article.
Maraviroc, as a Switch Option, in HIV-1-infected Individuals With Stable, Well-controlled HIV Replication and R5-tropic Virus on Their First Nucleoside/Nucleotide Reverse Transcriptase Inhibitor Plus Ritonavir-boosted Protease Inhibitor Regimen: Week 48 Results of the Randomized, Multicenter MARCH Study.
Pett SL, Amin J, Horban A, Andrade-Villanueva J, Losso M, Porteiro N, Sierra Madero J, Belloso W, Tu E, Silk D, Kelleher A, Harrigan R, Clark A, Sugiura W, Wolff M, Gill J, Gatell J, Fisher M, Clarke A, Ruxrungtham K, Prazuck T, Kaiser R, Woolley I, Arnaiz JA, Cooper D, Rockstroh JK, Mallon P, Emery S; Maraviroc Switch (MARCH) Study Group. Pett SL, et al. Clin Infect Dis. 2016 Jul 1;63(1):122-32. doi: 10.1093/cid/ciw207. Epub 2016 Apr 5. Clin Infect Dis. 2016. PMID: 27048747 Free PMC article. Clinical Trial.
Reply to "Issues on results of the external quality assessment for proviral DNA testing of HIV-1 Tropism in the Maraviroc Switch collaborative study".
Tu E, Swenson LC, Land S, Pett S, Emery S, Marks K, Kelleher AD, Kaye S, Kaiser R, Schuelter E, Harrigan R; MARCH Laboratory Group and the MARCH Study Group. Tu E, et al. Among authors: schuelter e. J Clin Microbiol. 2013 Dec;51(12):4287. doi: 10.1128/JCM.02207-13. J Clin Microbiol. 2013. PMID: 24243995 Free PMC article. No abstract available.